Archive: 2019

24

Nov2019

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

0  
November 24, 2019

20

Nov2019

Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With nab-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial

0  
November 20, 2019

14

Nov2019

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa

0  
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa   Highlights: Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy First prospective clinical study in advanced ... Read More
November 14, 2019

14

Nov2019

Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

0  
November 14, 2019

20

Jun2019

ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial

0  
June 20, 2019

03

Jun2019

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009)

0  
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa   June, 3 2019, Aadi Bioscience, Inc. (Aadi), Aadi Bioscience, Inc (Aadi), a privately held clinical stage biopharmaceutical company, today released preliminary data on the ongoing nab-sirolimus (ABI-009) registration trial (AMPECT) for Advanced ... Read More
June 3, 2019

31

May2019

ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

0  
May 31, 2019

20

Apr2019

Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor

0  
April 20, 2019

20

Apr2019

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

0  
April 20, 2019

20

Apr2019

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

0  
April 20, 2019